Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
Abvance Gets $3.9M Investment from Helmsley Trust For Insulin-Glucagon Drug
Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : T1D Exchange
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : T1D Exchange
Deal Size : Inapplicable
Deal Type : Inapplicable